The Cooper Companies, Inc. (NYSE:COO – Get Rating) has been given an average rating of “Buy” by the twelve analysts who cover the company, Marketbeat reports. Four investment analysts rated the stock with a hold recommendation and seven gave the company a buy recommendation. The 12-month average price target among analysts who have reported on the stock in the past year is $469.00.
A number of analysts have commented on the stock. Piper Sandler raised her price target on Cooper Companies shares from $490.00 to $500.00 in a Friday, March 4 research note. Needham & Company LLC assumed coverage for Cooper Companies stock in a Friday, April 8 research note. They issued a “holding” rating for the company. Stephens raised his price target on Cooper Companies shares from $430.00 to $500.00 and gave the company an “overweight” rating in a Monday, March 7 research note. Finally, StockNews.com took over coverage of Cooper company stocks in a Thursday, March 31 research note. They issued a “holding” rating for the company.
COO traded $8.37 during trading hours on Tuesday, hitting $319.98. 9,108 shares of the company were traded, against an average volume of 318,847. Cooper Companies has a 1-year low of $310.53 and a 1-year high of $463.59. The stock’s 50-day moving average is $397.50 and its two-hundred-day moving average is $401.73. The stock has a market capitalization of $15.78 billion, a price/earnings ratio of 16.92, a PEG ratio of 2.18 and a beta of 0.90. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt ratio of 0.34.
Cooper Companies (NYSE:COO – Get Rating) last announced its results on Thursday, March 3. The medical device company reported EPS of $3.24 for the quarter, beating the consensus estimate of $3.10 by $0.14. Cooper Companies had a net margin of 31.00% and a return on equity of 9.89%. The company posted revenue of $787.20 million in the quarter, compared to $739.30 million expected by analysts. In the same quarter a year earlier, the company posted earnings per share of $3.17. The company’s revenue increased 15.7% year over year. On average, equity research analysts expect Cooper Companies to post EPS of 14.09 for the current year.
In a similar vein, SVP Agostino Ricupati sold 5,607 shares of Cooper Companies in a trade that took place on Friday, March 18. The shares were sold at an average price of $421.51, for a total transaction of $2,363,406.57. The transaction was disclosed in a filing with the SEC, accessible via this link. Additionally, director Robert S. Weiss sold 13,039 shares of Cooper Companies in a trade that took place on Tuesday, March 29. The stock was sold at an average price of $415.24, for a total transaction of $5,414,314.36. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 19,646 shares of the company worth $8,195,614. 1.70% of the shares are currently held by insiders.
A number of large investors have been buying and selling stocks recently. Tealwood Asset Management Inc. bought a new position in Cooper Companies during Q3 for a value of approximately $1,390,000. Van ECK Associates Corp increased its holdings in Cooper Companies by 13.3% during the fourth quarter. Van ECK Associates Corp now owns 8,946 shares of the medical device company worth $3,748,000 after acquiring 1,048 additional shares in the last quarter. CIBC Asset Management Inc. increased its holdings in Cooper Companies by 2.1% during the 4th quarter. CIBC Asset Management Inc. now owns 11,208 shares of the medical device company worth $4,695,000 after acquiring 231 additional shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in Cooper Companies by 0.7% during the fourth quarter. Mutual of America Capital Management LLC now owns 6,504 shares of the medical device company worth $2,725,000 after acquiring 48 additional shares in the last quarter. Finally, First Trust Advisors LP increased its holdings in Cooper Companies by 2.4% during the 4th quarter. First Trust Advisors LP now owns 92,478 shares of the medical device company worth $38,743,000 after acquiring 2,176 additional shares in the last quarter. Institutional investors and hedge funds own 98.38% of the company’s shares.
Company Profile Cooper Companies (Get a rating)
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures and markets contact lens wearers. The Company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lenses, including lenses that correct presbyopia and farsightedness; and toric and multifocal lenses including lenses correcting vision problems, such as astigmatism, presbyopia, myopia, dry eye and eye strain in the Americas, Europe, Middle East, Africa and Asia-Pacific.
Receive daily news and reviews for Cooper Companies – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Cooper companies and related companies with MarketBeat.com’s free daily email newsletter.